Loading...
•
Mar 31, 2024
Tempest Q1 2024 Earnings Report
Tempest reported financial results for the first quarter of 2024 and provided a corporate update.
Key Takeaways
Tempest Therapeutics reported a net loss of $7.9 million for the first quarter of 2024. The company ended the quarter with $32.3 million in cash and cash equivalents and expects to fund operations into the second quarter of 2025.
Advanced TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAP.
Reported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual Meeting.
Published positive data from the Phase 1 Trial of TPST-1120 in patients with advanced solid tumors in the Journal of Cancer Research Communications.
Presented new data at the SITC 2024 Spring Scientific Meeting elucidating the mechanism of TPST-1120 and supporting its potential in multiple cancers.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...